Corvus Pharmaceuticals, Inc. (CRVS)
Largest Insider Buys in Sector
CRVS Stock Price History Chart
CRVS Stock Performance
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of …
Insider Activity of Corvus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Corvus Pharmaceuticals, Inc. have bought $1.03M and sold $0 worth of Corvus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Corvus Pharmaceuticals, Inc. have bought $2.67M and sold $23.37M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILLER RICHARD A MD (President and CEO) — $1,000,000. Jones William Benton (See Remarks) — $34,624.
The last purchase of 577,634 shares for transaction amount of $1,000,000 was made by MILLER RICHARD A MD (President and CEO) on 2024‑05‑06.
List of Insider Buy and Sell Transactions, Corvus Pharmaceuticals, Inc.
| 2024-05-06 | President and CEO | 577,634 1.0676% | $1.73 | $1,000,000 | +110.99% | |||
| 2024-05-06 | See Remarks | 20,000 0.037% | $1.73 | $34,624 | +110.99% | |||
| 2023-05-15 | director | 10,000 0.0202% | $2.45 | $24,500 | -23.08% | |||
| 2022-12-20 | See Remarks | 20,000 0.0435% | $0.79 | $15,800 | +85.90% | |||
| 2022-12-14 | President and CEO | 10,000 0.021% | $0.78 | $7,812 | +78.13% | |||
| 2022-12-14 | Chief Financial Officer | 4,000 0.009% | $0.84 | $3,364 | +78.13% | |||
| 2022-12-13 | President and CEO | 50,000 0.1031% | $0.74 | $37,015 | +84.18% | |||
| 2022-12-13 | Chief Financial Officer | 30,000 0.0621% | $0.74 | $22,275 | +84.18% | |||
| 2022-06-24 | President and CEO | 5,000 0.0123% | $1.00 | $4,985 | +4.60% | |||
| 2022-06-02 | President and CEO | 890 0.002% | $1.01 | $899 | -7.89% | |||
| 2022-03-31 | President and CEO | 15,000 0.0321% | $1.64 | $24,534 | -44.51% | |||
| 2022-03-16 | Chief Financial Officer | 13,878 0.0307% | $1.65 | $22,899 | -42.38% | |||
| 2022-03-15 | President and CEO | 5,000 0.0117% | $1.59 | $7,950 | -36.44% | |||
| 2021-10-01 | Sale | 10 percent owner | 2M 4.4342% | $4.96 | $9.93M | -67.36% | ||
| 2021-09-30 | Sale | 10 percent owner | 3M 6.7156% | $5.04 | $15.13M | -67.46% | ||
| 2021-09-20 | Sale | 1.11M 2.4922% | $6.09 | $6.76M | -73.58% | |||
| 2021-09-20 | Sale | 1.11M 2.4922% | $6.09 | $6.76M | -73.58% | |||
| 2021-08-20 | President and CEO | 10,000 0.0229% | $1.93 | $19,254 | -5.76% | |||
| 2021-05-04 | President and CEO | 35,714 0.0833% | $2.80 | $99,999 | -13.38% | |||
| 2021-02-17 | 1.29M 3.6216% | $3.50 | $4.5M | -23.75% |
Insider Historical Profitability
| MILLER RICHARD A MD | President and CEO | 577634 0.8989% | $9.01 | 29 | 0 | +5.51% |
| Jones William Benton | See Remarks | 153773 0.2393% | $9.01 | 2 | 0 | +85.9% |
| ORBIMED ADVISORS LLC | 6943654 10.806% | $9.01 | 19 | 1 | +4.76% | |
| Thompson Peter A. | 6943654 10.806% | $9.01 | 19 | 1 | +4.76% | |
| Novo Holdings A/S | 10 percent owner | 1389498 2.1624% | $9.01 | 3 | 5 | +12.06% |
Institutional Investor Ownership
| OrbiMed | $12.36M | 11.1 | 6.94M | 0% | +$0 | 0.1 | |
| Adams Street Partners Llc | $5.83M | 5.24 | 3.28M | 0% | +$0 | 2.32 | |
| Samlyn Capital, LLC | $4.18M | 3.75 | 2.35M | -5.92% | -$263,254.87 | 0.07 | |
| The Vanguard Group | $2.66M | 2.39 | 1.49M | +10.57% | +$254,048.68 | <0.0001 | |
| Renaissance Technologies | $1.13M | 1.02 | 637,032 | +8.44% | +$88,294.47 | <0.01 |